Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028947 | 1.00 | L3MBTL1 (0.49) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18559596 | 0.98 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL25003559 | 0.98 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18842833 | 0.98 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL20940017 | 0.98 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL26751590 | 0.98 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNASMN1; SMN2 | |
| SCHEMBL18473557 | 0.97 | L3MBTL1 (0.51) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18910475 | 0.95 | L3MBTL1 (0.47) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL25067012 | 0.95 | L3MBTL1 (0.47) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL11528137 | 0.95 | L3MBTL1 (0.49) | L3MBTL1TDP1TBXAS1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210355103-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2021-11-18 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180051020-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 | HYDRA BIOSCIENCES INC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170265474-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170265474-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | DDT, BCHE, BAK1 | L3MBTL1 169/4885TDP1 3842/4885TBXAS1 2717/4885 |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | L3MBTL1 1366/4885TDP1 220/4885TBXAS1 4563/4885 |
| US-20180051020-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 | TRPA1, TRPV1, TRPV2 | L3MBTL1 2897/4885TDP1 1610/4885TBXAS1 797/4885 |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | L3MBTL1 1260/4885TDP1 1551/4885TBXAS1 2463/4885 |
| US-20210355103-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARN | L3MBTL1 1381/4885TDP1 200/4885TBXAS1 1142/4885 |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | L3MBTL1 2145/4885TDP1 4315/4885TBXAS1 2497/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | L3MBTL1 3452/4885TDP1 3915/4885TBXAS1 1494/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | L3MBTL1 3452/4885TDP1 3915/4885TBXAS1 1494/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | L3MBTL1 3833/4885TDP1 1046/4885TBXAS1 531/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | L3MBTL1 3832/4885TDP1 710/4885TBXAS1 270/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | L3MBTL1 1378/4885TDP1 798/4885TBXAS1 1766/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | L3MBTL1 3832/4885TDP1 710/4885TBXAS1 270/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | L3MBTL1 2126/4885TDP1 4533/4885TBXAS1 3148/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | L3MBTL1 3832/4885TDP1 710/4885TBXAS1 270/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | L3MBTL1 4442/4885TDP1 370/4885TBXAS1 198/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | L3MBTL1 2309/4885TDP1 1172/4885TBXAS1 1261/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | L3MBTL1 2237/4885TDP1 1069/4885TBXAS1 1615/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | L3MBTL1 3833/4885TDP1 1046/4885TBXAS1 531/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | L3MBTL1 2221/4885TDP1 3153/4885TBXAS1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.